LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Methods Compared Classifying Intensity of Soil-Transmitted Helminth Infections

By LabMedica International staff writers
Posted on 23 Jul 2020
Image: The FECPAKG2 is an internet connected, image based diagnostic platform scientifically validated to conduct fecal egg count (FEC) tests (Photo courtesy of Techion).
Image: The FECPAKG2 is an internet connected, image based diagnostic platform scientifically validated to conduct fecal egg count (FEC) tests (Photo courtesy of Techion).
Soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichiura) and the hookworms, Necator americanus and Ancylostoma duodenale affect one quarter of the world population, and are responsible for the loss of more than three million disability-adjusted life years (DALYs).

There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.

An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.

The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.

The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System

Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more